These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26324672)

  • 21. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving hypertension control in patients at cardiovascular risk: the case for telmisartan-based therapy.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(1):45-6. PubMed ID: 21298207
    [No Abstract]   [Full Text] [Related]  

  • 24. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.
    Kjeldsen S; Mancia G; Schmieder R; Mattheus M; Unger T
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):673-82. PubMed ID: 23750676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Biomarkers in Hypertensive Patients with Medical Treatment-Results from the Randomized TEAMSTA Protect I Trial.
    Jagodzinski A; Neumann JT; Ojeda F; Sörensen NA; Wild P; Münzel T; Zeller T; Westermann D; Blankenberg S
    Clin Chem; 2017 Dec; 63(12):1877-1885. PubMed ID: 28904053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
    Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
    Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.
    Meno H; Inou T; Tanaka M; Tsuchiya Y; Shiga Y; Kobayashi K; Nakamura Y; Ota T; Kubara I
    Arzneimittelforschung; 2012 Sep; 62(9):414-9. PubMed ID: 22773432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.
    Kulkarni RB; Kulkarni BN; Hariharan RS; Naikwadi A; Gawde A; Baliga V; Desai A
    J Indian Med Assoc; 2005 Mar; 103(3):187-91. PubMed ID: 16173297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.
    Ahrens K; Bramlage P
    Drugs Today (Barc); 2010 May; 46(5):339-50. PubMed ID: 20517535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.